

Administration

Adopted: XX-XX-XXXX

Purpose

Administration sessions involve the supervised facilitation of a patient's medical psilocybin experience within an approved setting.

Administration sessions serve to:

- Provide a safe and supportive environment for psilocybin administration.
- Maintain patient physical and psychological safety throughout the experience.
- Support the patient during altered states of consciousness.
- Monitor physiological and psychological responses during administration.
- Ensure compliance with regulatory and facility safety requirements.
- Facilitate a therapeutic environment conducive to introspection, emotional processing, and insight.

Administration sessions occur after completion of required preparation sessions and prior to post-session integration.

Minimum Administration Requirements

Administration sessions must meet the following minimum requirements:

- Administration must occur within an approved setting
- The Facilitator must be present and available to provide support for the duration of the administration session.
- Administration must be documented in the patient's clinical record.
- Administration sessions must comply with all applicable **state regulations, facility policies, and safety protocols.**

Informed Consent Confirmation

Prior to administration, facilitators must reconfirm informed consent through direct discussion with the patient. This discussion must include:

- Confirmation that the patient understands the nature of psilocybin administration
- Potential psychological and physical effects

- Possible intensity or unpredictability of the experience
- Patient rights to postpone, cancel, or delay a session at any time before administration
- Notification that administration is not covered by insurance
- Show patient the pt bill of rights
- Patient confidentiality form shall be signed before administration.
- Reaffirm boundaries with patient before administration.
- Consent confirmation must be documented prior to administration.

Dosage and Administration

Psilocybin products must be administered according to the Psychedelic Therapists' guidance/recommendation.

Administration procedures must include:

- Verification of product identity and dosage
- Confirmation that the product was obtained through authorized channels
- Documentation of the dosage administered
- Observation of ingestion or administration by the patient
- Patients must voluntarily self-administer the product.

Facilitators must not coerce, pressure, or physically administer psilocybin to patients.

Facilitator Monitoring and Support

Facilitators must remain present and attentive throughout the administration session.

Responsibilities include:

- Observing patient behavior and emotional responses
- Providing reassurance and grounding support when needed
- Monitoring for signs of distress or adverse reactions
- Maintaining a calm and supportive presence
- Facilitators should generally allow patients to experience the session internally, offering guidance only when necessary to maintain safety or stability.

Managing Difficult Experiences

Patients may encounter emotionally challenging or intense experiences during administration.

Facilitators must be prepared to provide supportive interventions including:

- Verbal reassurance and grounding techniques
- Encouragement of breathing or relaxation strategies
- Adjustments to environmental conditions (lighting, music, position)
- Facilitators must avoid interventions that unnecessarily interrupt the patient's experience unless safety concerns arise.

Safety and Emergency Procedures

Administration sessions must include clear protocols for managing emergencies.

Facilitators must have access to:

- Emergency medical services contact procedures
- Facility emergency protocols
- Fire and environmental safety procedures
- Communication systems for requesting assistance

If a medical or psychological emergency occurs, facilitators must prioritize patient safety and follow established emergency procedures.

Session Completion and Recovery

At the conclusion of the administration experience, patients must be monitored until they are stable and capable of safely leaving the facility.

Facilitators must ensure:

- Patients demonstrate adequate orientation and physical stability
- Patients have access to hydration and rest
- Patients understand post-session safety instructions

Patients must be reminded:

- Not to operate a motor vehicle for at least **24 hours following administration**; and
- Qualified patients are not immune from civil nor criminal liability arising out of the operation of a motor vehicle if driving while under the influence of psilocybin.

Transition to Integration

Before leaving the facility, patients should receive guidance regarding the integration process.

Facilitators should:

- Encourage reflection on the experience
- Provide information about scheduled integration sessions
- Offer recommendations for post-session self-care

Patients must be informed of how to contact facilitators or program staff if concerns arise following administration.

Documentation

Facilitators must document administration sessions in the patient's clinical record.

Documentation must include:

- Date and duration of administration
- Identity of facilitator(s) present
- Dosage administered
- Patient observations during the session
- Any supportive interventions provided
- Confirmation of safe session completion

Documentation must also confirm that the patient was released safely.

Timing and Clinical Oversight

Administration sessions should allow adequate time for the full psilocybin experience and recovery period.

Programs must ensure:

- A facilitator-to-patient ratio of 1:3
- Adequate staffing to maintain safety
- Compliance with regulatory and professional standards

Administration must not be rushed or conducted in a manner that compromises patient safety or therapeutic integrity.